The value of oral immunotherapy.
On July 10, 2019, the Institute for Clinical and Economic Review (ICER) published its final report on the effectiveness and value of AR101 and Viaskin® Peanut for peanut allergy1 . At a threshold of $50,000 USD per quality-adjusted life-year (QALY), the report concludes that the limit of cost-effectiveness is reached at an annual cost of $2,369 per year for ARA101 and $1,508 for Viaskin® peanut, which is in line with recent estimates from Shaker and Greenhawt2 .